The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Loqtorzi toripalimab Additional monitoring | Topalliance Biosciences Europe Limited | Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma | 🇪🇺 EU 2024-09-19 | Order → |
| Tuznue trastuzumab Additional monitoring | Prestige Biopharma Belgium | Breast Neoplasms | 🇪🇺 EU 2024-09-19 | Order → |
| Vevizye ciclosporin | Laboratoires Théa | Keratoconjunctivitis Sicca | 🇪🇺 EU 2024-09-19 | Order → |
| Vyloy zolbetuximab OrphanAdditional monitoring | Astellas Pharma Europe B.V. | Stomach Neoplasms; Esophageal Neoplasms | 🇪🇺 EU 2024-09-19 | Order → |
| Eksunbi ustekinumab Biosimilar | Samsung Bioepis NL B.V. | Crohn Disease; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic | 🇪🇺 EU 2024-09-12 | Order → |
| Akantior polihexanide Orphan | SIFI SPA | Acanthamoeba Keratitis | 🇪🇺 EU 2024-08-22 | Order → |
| Balversa erdafitinib Additional monitoring | Urologic Neoplasms | 🇪🇺 EU 2024-08-22 | Order → | |
| Enzalutamide Viatris enzalutamide Generic | Viatris Limited | Prostatic Neoplasms | 🇪🇺 EU 2024-08-22 | Order → |
| Eurneffy epinephrine | ALK-Abelló A/S | Anaphylaxis | 🇪🇺 EU 2024-08-22 | Order → |
| mResvia respiratory syncytial virus mRNA vaccine Additional monitoring | Moderna Biotech Spain, S.L. | Respiratory Syncytial Virus Infections | 🇪🇺 EU 2024-08-22 | Order → |
| Nilotinib Accord nilotinib Generic | Accord Healthcare S.L.U. | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2024-08-22 | Order → |
| Ordspono odronextamab OrphanConditionalAdditional monitoring | Regeneron Ireland Designated Activity Company (DAC) | Lymphoma, Follicular | 🇪🇺 EU 2024-08-22 | Order → |
| Piasky crovalimab Additional monitoring | Roche Registration GmbH | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2024-08-22 | Order → |
| Steqeyma ustekinumab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Psoriasis; Arthritis, Psoriatic; Crohn Disease | 🇪🇺 EU 2024-08-22 | Order → |
| Tauvid flortaucipir (18F) Additional monitoring | Eli Lilly Nederland B.V. | Radionuclide Imaging | 🇪🇺 EU 2024-08-22 | Order → |
| Winrevair sotatercept OrphanPRIMEAdditional monitoring | Merck Sharp & Dohme B.V. | Hypertension, Pulmonary | 🇪🇺 EU 2024-08-22 | Order → |
| Adzynma rADAMTS13 OrphanExceptional circumstancesAdditional monitoring | Takeda Manufacturing Austria AG | Purpura, Thrombotic Thrombocytopenic | 🇪🇺 EU 2024-08-01 | Order → |
| GalliaPharm gallium (68Ga) chloride;germanium (68Ge) chloride | Eckert & Ziegler Radiopharma GmbH | Radionuclide Imaging | 🇪🇺 EU 2024-08-01 | Order → |
| Avzivi bevacizumab BiosimilarAdditional monitoring | FGK Representative Service GmbH | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical | 🇪🇺 EU 2024-07-26 | Order → |
| Dasatinib Accord Healthcare dasatinib Generic | Accord Healthcare S.L.U. | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2024-07-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.